The use of a low-frequency radiofrequency field (RFF) of 27.125 MHz adjuvant to radiotherapy may be beneficial, as they have been shown to exhibit in vitro radiosensitizing and radioprotecting effects in malignant and normal cells, respectively, with the possibility of a significant dose reduction. This observation, however, appears to be dependent on the magnitude of the frequency used to modulate the field. Here, the effect of modulating a 27.125 MHz with 100, 1000, 2000, and 4000 Hz fields on the radiosensitivity of four cell lines (DU145: p53 mutant prostate cancer; MeWo: p53 mutant melanoma; Be11: p53 wild-type melanoma; L132: p53 wild-type normal lung fibroblasts) was evaluated using clonogenic survival. The data demonstrates that RFF-medi-ated radiosensitization does not consistently increase with increasing the modulating frequency. In this panel of cell lines, radiosensitization is highest in p53 wild-type cells and peaks at a modulating frequency of 1000 Hz when irradiated to 6 Gy. An expansion of the panel of cell lines could assist in validating the roles of modulating frequencies and gene status in the potential application of RFFs as radiosensitizers and radioprotectors, especially in settings of hypofractionation.
展开▼
